Introduction
============

Hypomagnesemia contributes to the pathophysiology of diabetes and metabolic syndrome.[@b1-dmso-11-389],[@b2-dmso-11-389] In one study, there was a graded inverse relationship between serum magnesium (Mg) levels and incident type 2 diabetes; this association remained significant even after adjusting for potential confounders, including diuretic use.[@b3-dmso-11-389] This relationship implies a clear need to consider Mg as a potential supplement for treating type 2 diabetes. Further, there is abundant evidence demonstrating the prevalence and adverse clinical consequences of Mg deficiency in patients with diabetes mellitus. It would be prudent for physicians treating such patients to consider Mg deficiency as a contributing factor in many diabetic complications.[@b4-dmso-11-389]

The lower normal serum Mg level at the clinical laboratory in Dasman Diabetes Institute (DDI; Dasman, Kuwait) is 0.74 mmol/L, but this level only represents \<1% of the total body Mg level. Importantly, a significant proportion of patients with normal serum Mg levels may have cellular Mg deficiency because the highest level of Mg is in skeletal muscles, bones, and other organs. Thus, intracellular Mg levels compared with serum Mg levels are more representative end points of total body Mg deficiency. Sublingual epithelial cells are a rapidly renewing, homogeneous cell population that reflects the current total body intracellular mineral status. A study of intracellular Mg levels demonstrated that Mg levels in sublingual epithelial cells correlated better with Mg levels in heart tissue (obtained during bypass surgery) than with serum Mg levels.[@b5-dmso-11-389],[@b6-dmso-11-389]

Our results may support a wider application of the cellular Mg assay not only in patients with diabetes or metabolic syndrome but also in those with cancer, cardiovascular disease, or other diseases where Mg and glucose homeostasis may be impaired.

The anti-inflammatory effects of oral Mg supplementation in patients with diabetes or metabolic syndrome and those with low serum Mg levels have been studied with increased interest in recent years.[@b1-dmso-11-389],[@b7-dmso-11-389] In the present open-label clinical trial, 47 hypomagnesemic patients with type 2 diabetes were enrolled; for 3 months, they were administered Mg-l-lactate tablets that provided 336 mg of Mg daily. The repletion of Mg levels in serum and oral epithelial cells was compared with changes in C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), hemoglobin A1c (HbA1c), and the oxidative stress biomarker 8-isoprostane.

Subjects, materials, and methods
================================

Patients and eligibility criteria
---------------------------------

At the DDI, from March 2015 until April 2016, the records of 1022 patients with type 2 diabetes were screened for inclusion. Inclusion criteria required the presence of hypomagnesemia (serum levels \<0.74 mmol/L), aged between 21 and 70 years, and the presence of at least one abnormal indicator of inflammation. Patients were excluded if they suffered from significant gastrointestinal disorders (eg, chronic diarrhea), chronic inflammatory disorders (eg, psoriasis), impaired renal function (estimated glomerular filtration rate \[eGFR\] \<60 mL/min), hypertension (eg, angiotensin-converting enzyme inhibitors and diuretics), heart block (eg, electrocardiographic \[ECG\] evidence of left bundle branch block), or heart failure (eg, treated with aldosterone antagonists). Patients who had used Mg supplements within 3 months and pregnant women were also excluded.

This study was conducted in accordance with the Good Clinical Practice criteria and according to the tenets of the Declaration of Helsinki of 2013. The study protocol and informed consent form were approved by the ethics committee of the DDI before initiating the study. All patients provided written informed consent before inclusion, in compliance with 21 case report forms (CRF) Part 50, and their data were recorded in CRF specific for the study including an adverse event questionnaire.

Further, patients were classified according to the World Health Organization obesity classification guidelines (obese when the body mass index \[BMI\] was ≥30.0 kg/m^2^).[@b8-dmso-11-389]

Study design
------------

This was an open-label clinical trial in which Mg-l-lactate was supplemented for 12 weeks in 47 patients with type 2 diabetes and documented hypomagnesemia. Patients initially underwent a clinical and laboratory evaluation, and blood samples were obtained for HbA1c and creatinine level estimation and for assays of serum and cellular Mg level determination. After 12 weeks, the patients underwent a subsequent evaluation. The study was registered under <https://clinicaltrials.gov/ct2/show/NCT01980459>.

The trial design was changed from an initially proposed randomized parallel group placebo study to an open-label trial because of the discoloration of placebo tablets; since the placebo tablets were discolored, patients would be aware that they were in the placebo arm. Therefore, the number of groups was reduced from two to one with 50 patients. Study end points, patient screening, the Mg tablet supplementation protocol, and laboratory assessments remained the same as in the original proposal. The change in design was approved by the ethical review committee at the DDI (Kuwait) and by the Office of Human Research--Institutional Review Board at George Washington University (Washington, DC, USA).

Intervention
------------

Patients received Mg supplementation twice a day; they received 336 mg of elemental Mg, which approximates the recommended daily allowance for adults. Mg tablets (7 mEq) were provided by Niche Pharmaceuticals, Inc. (Southlake, TX, USA; Lot \# B060057BA). This formulation of Mg-l-lactate has been reported to have a bioavailability of 41% (compared with Mg oxide), and its sustained release has a low risk of gastrointestinal side effects. The longer time (3 months) of treatment is based on a prior Mg treatment trial of hypomagnesemic patients who achieved a 20% increase in serum Mg levels after 3 months.[@b9-dmso-11-389]

At each clinic visit, patients were provided with sufficient tablets for 1 month of treatment. Data were recorded in the CRF at each clinic visit. Compliance was assessed by counting the number of tablets, and patients returning \<20% of the tablets were considered compliant. Patients were asked to continue their regular medication and diet as usual and were advised not to take any other supplements that might contain Mg.

Primary and secondary end points
--------------------------------

The study had two coprimary end points: the change in Mg levels in the serum and mucosal cells between the baseline and the 3-month visit. The change in the following secondary end points from the baseline was also measured at the 3-month visit: CRP, TNF-α, 8-isoprostane, and HbA1c.

At the initiation of the clinical trial, assays of serum and cellular Mg and inflammatory biomarker levels were performed; serum Mg levels were monitored at 1 and 2 months. Three months later, both tests were repeated. Body weight, blood pressure, and heart rate were measured at every clinic visit. ECG was conducted at the screening visit and at the 2- and 3-month visits for safety. Any ECG abnormality was recorded in the CRF.

Clinical laboratory blood tests
-------------------------------

Clinical laboratory tests were performed for each patient before the start of Mg supplementation (screening/baseline) and at the final patient visit. Assays of serum Mg, HbA1c, and CRP levels were performed. Serum Mg and HbA1c levels were monitored at 1 and 2 months after the treatment was started, and all tests were repeated at the final visit after 3 months.

Intracellular Mg analysis or epithelial cell mineral analysis
-------------------------------------------------------------

Sublingual epithelial cells were noninvasively obtained from each patient and were fixed on slides before performing assays for Mg levels by analytical scanning electron microscopy (ASEM) using the computerized elemental X-ray analysis programs. Patient cell samples before and after Mg treatment were obtained at the baseline and at the end of 3 months.

Sublingual epithelial cell specimen collection
----------------------------------------------

The patients fasted overnight and were asked to rinse their mouth with water; sublingual soft tissue on the floor of the mouth was scraped using a wooden spatula. Cells were transferred on specially prepared slides (Intracellular Diagnostics, Inc., Medford, OR, USA). Immediately, the cells were fixed chemically (Pap-Pak® Cytology Fixative; Camarillo, CA, USA), allowed to dry, and stored at 4°C until analysis. All collected samples were shipped to Dr. Burton Silver (Intracellular Diagnostics, Inc.), who was our collaborator.

Each epithelial cell sample was viewed using ASEM and was analyzed by the elemental energy-dispersive X-ray analysis method. This technique uses energy-dispersive X-ray microanalysis (EXAtm) for the noninvasive intracellular measurement of Mg and potassium (K) (USA patent Number: 4-717-826, B.S.) levels. Sublingual epithelial cells were chosen as markers as they are easily accessible, noncornified, and aerobic; they have a high cytoplasm-to-nucleus ratio, turnover in \<3 days, long shelf life, and they exhibit 99% viability. The excitation of cellular atoms displaces inner orbital electrons, which are replaced by electrons from higher energy cells releasing fluoresced X-rays, which allows the quantitation of intracellular elements. EXAtm units equal the X-ray intensity (peak divided by background) divided by unit cell volume. EXAtm units are converted to milliequivalents per liter by a conversion constant for each element derived from a reference standard of a highly stable matrix synthetic glass containing known amounts of the elements to be analyzed. The standard was certified by the National Bureau of Standards (Washington, DC, USA) and Corning Diagnostics (Cambridge, MA, USA).

Oxidative stress and inflammatory biomarkers
--------------------------------------------

### 8-Isoprostane, TNF-α, and CRP

Plasma samples were collected from ethylenediaminetetraacetic acid-treated blood samples obtained at the baseline for all patients and at their final visit after 3 months of treatment with Mg. The levels of inflammatory biomarkers (CRP and TNF-α) and the oxidative reactive oxygen species (ROS) stress biomarker 8-isoprostane were assessed.

All plasma samples were stored at −80°C before analysis. The levels of the biomarkers were measured using sandwich enzyme-linked immunosorbent assay kits, and color intensity was read on a plate reader at the recommended wavelength following the instruction manual for each kit. A multimode microplate reader was used for measuring absorbance (Synergy H4; BioTek Instruments, Winooski, VT, USA), and the software Gen5™ 1.10 was used for analysis.

For 8-isoprostane detection, plasma samples were treated further with 0.005% butylated hydroxytoluene (Sigma-Aldrich Corp., Albuch, Germany) before being frozen. 8-Isoprotane levels were assessed using an 8-isoprostane Enzyme immunoassay (EIA) kit (Catalog No. 516351; Cayman Chemical, Ann Arbor, MI, USA).

Absorbance readings were averaged, nonspecific binding was subtracted, and the four-parameter logistic (4-PL) regression curve fit was generated for standards with known concentration; the sample concentration was interpolated, and the dilution factor used was corrected according to assay kit instructions. The software GraphPad Prism was used for the 4-PL fit of the standard samples to then extrapolate the sample concentrations.

Statistical analyses
--------------------

Changes in the mean levels of the primary and secondary end points were tested using paired *t*-tests. Most data were expressed as mean ± SD: ^\*^*p*\<0.05, \*\**p*\<0.01, and \*\*\**p*\<0.001.

Results
=======

Of the 1022 patients with type 2 diabetes who were screened, 225 met the renal inclusion criteria (creatinine level \<140 μmol/L, eGFR =60 mL/min/1.73 m^2^): 77 refused to take screening for Mg levels, 61 had normal Mg levels, and 87 had hypomagnesemia (average serum Mg level =0.68±0.06 mmol/L) and CRP levels (average =0.32±0.54). Of the 62 patients who agreed to participate, 47 completed the trial, eight did not receive the allocated intervention and were excluded from the trial mainly due to abnormal ECG results, and seven dropped out of the study. The 47 study patients were classified according to their BMI, with 15 patients classified as nonobese and 32 as obese.

Ultimately, data from the 47 patients were analyzed, with intracellular Mg levels analyzed in 46 patients and isoprostane levels analyzed in 25 patients. The study flow diagram is illustrated in [Figure S1](#SD1-dmso-11-389){ref-type="supplementary-material"}.

Demographics and clinical characteristics
-----------------------------------------

[Table S1](#SD2-dmso-11-389){ref-type="supplementary-material"} summarizes the demographic and clinical characteristics of all patients studied (25 \[53%\] male and 22 \[47%\] female patients; 32 \[68%\] obese and 15 \[32%\] nonobese). The average patient age was 52 years (range, 27--69 years) with the majority of the patients (22) within the 50--59 years of age range.

Primary and secondary outcomes
------------------------------

[Table 1](#t1-dmso-11-389){ref-type="table"} shows the results of the clinical laboratory and biochemical parameters assessed for all the patients at baseline and at the end of the trial after completing their final visit. The laboratory values for all the patients are further listed dividing the patients in obese and nonobese groups. At the end of the 3-month supplementation period with an average of 22.8 g of Mg-l-lactate per patient, both obese and nonobese Mg-supplemented subjects showed significant increase in their serum Mg levels (0.71±0.06 mmol/L to 0.73±0.06 mmol/L, *p*\<0.0001) and also significant increase in their intracellular Mg levels (33.1±1.25 mEq/L to 35.55±5.6 mEq/L, *p*\<0.01). Patients also showed a significant reduction in their TNF-α levels from 9.1±1.7 to 6.1±2.7 (*p*\<0.0001). Metabolic control as measured by HbA1c however was not altered significantly (HbA1c, 8.1±1.7% vs 7.9±1.9%), and CRP also showed no significant changes at the end of the supplementation period.

Review of the serum Mg mean values pre- and posttreatment shows a significant difference in both groups, but only reaching the normal level of 0.74 mEq/L in the nonobese group ([Figure 1A and B](#f1-dmso-11-389){ref-type="fig"}); the intracellular Mg mean values showed that both obese and nonobese patients had significant increases above the normal level of 34 mEq/L ([Figure 1C and D](#f1-dmso-11-389){ref-type="fig"}). When comparing serum and intracellular Mg levels before and after treatment and correlating it to patient age, no statistical significance was noted among the different age groups neither in the basal levels of the patients nor in their response to Mg supplementation.

For the inflammatory biomarkers, both TNF-α and CRP data were analyzed. TNF-α decreased ([Figure 2A](#f2-dmso-11-389){ref-type="fig"}), while no significant effect was observed in the CRP levels ([Figure 2B](#f2-dmso-11-389){ref-type="fig"}). The decrease in TNF-α levels was evident in both subgroups (obese and nonobese); however, the decrease in the obese group was larger than in the nonobese group ([Figure 2D](#f2-dmso-11-389){ref-type="fig"}). No significant effect was observed in the CRP levels of the subgroups ([Figure 2E](#f2-dmso-11-389){ref-type="fig"}).

A significant decrease in isoprostane was observed in the patients with high baseline levels ([Figure 2C](#f2-dmso-11-389){ref-type="fig"}); when subgrouping patients into obese and nonobese, the decrease in the obese group was statistically significant, but the decrease in the nonobese patients did not reach statistical significance ([Figure 2F](#f2-dmso-11-389){ref-type="fig"}). The red line indicates the normal plasma 8-isoprostane level (50 pg/mL) normally seen in healthy individuals.

The elemental X-ray analysis procedure for the intracellular Mg determination provided quantitative data for the cellular mineral balance of several elements including K, calcium, sodium, chloride, and phosphorus. [Figure 3](#f3-dmso-11-389){ref-type="fig"} shows the intracellular K levels at baseline and after 3 months of Mg supplementation in all patients ([Figure 3A](#f3-dmso-11-389){ref-type="fig"}) and in patients subgrouped into obese and nonobese ([Figure 3B](#f3-dmso-11-389){ref-type="fig"}). The reference range for intracellular K is 80.0--240 mEq/L).

Mg treatment compliance
-----------------------

Overall, patient compliance was assessed by dividing the number of Mg tablets consumed (calculated by subtracting the number of tablets returned from the total number of tablets dispensed) by the total number of tablets prescribed. Four patients took \<80% of the dispensed Mg tablets (one of them took \<60%).

Adverse events
--------------

All adverse events that occurred between the screening and last visit were recorded on the adverse event page of the CRF. Patients were able to comply with the twice-a-day dose schedule without significant side effects, and no dropouts were reported due to adverse events. Four patients reported mild-to-moderate gastrointestinal/abdominal symptoms, with a potential relationship to the intake of Mg tablets.

Discussion
==========

Despite the evident role of hypomagnesemia in the outcome of diabetic morbidity, less clinical emphasis has been placed on the long-term treatment of hypomagnesemia in patients with diabetes.[@b10-dmso-11-389] The link between Mg levels and diabetes was strengthened in reports which demonstrated that oral Mg supplementation restored serum Mg levels, significantly improved plasma glucose levels after a 2-hour oral glucose tolerance test, and improved parameters of insulin sensitivity and metabolic control in patients with type 2 diabetes and with decreased serum Mg levels.[@b11-dmso-11-389],[@b12-dmso-11-389] Hypomagnesemia has been reported to potentially increase insulin resistance through a mechanism that is not yet clear; insulin resistance has also been associated with hypertension and atherosclerotic cardiovascular disease in several reports.[@b13-dmso-11-389]--[@b15-dmso-11-389] A meta-analysis of randomized double-blind controlled trials by Song et al showed that oral Mg supplementation for 4--16 weeks may be effective in reducing plasma fasting glucose levels and raising high-density lipoprotein cholesterol in patients with type 2 diabetes, although the benefits on the long-term glycemic control as reflected by HbA1c levels remain to be determined.[@b16-dmso-11-389]

In an elegant review by Gommers et al, intracellular Mg was reported to play a role in the development of insulin resistance, with Mg affecting insulin receptor phosphorylation and in turn hypomagnesemia enhancing insulin resistance.[@b15-dmso-11-389] Nadler et al documented serum and erythrocyte intracellular Mg deficiency in patients with type 2 diabetes compared with healthy control subjects and showed that, in patients with type 2 diabetes, who received 400 mg oral Mg supplementation daily for 8 weeks, intracellular Mg levels were restored to normal levels with no significant increase in serum Mg levels. The intracellular Mg levels were determined in erythrocytes by a nuclear magnetic resonance-based research technique.[@b13-dmso-11-389]

There is a clear need for an intracellular Mg assessment method that can be clinically applied.[@b17-dmso-11-389] In our study, we assessed the efficacy of oral Mg supplementation on restoring cellular and serum Mg levels and the effects on circulating levels of CRP, TNF-α, 8-isoprostane, and other glucose intolerance biomarkers in patients with type 2 diabetes.

The initial lower epithelial K levels observed in patients with type 2 diabetes might reflect the decreases in intracellular Mg levels.[@b18-dmso-11-389] A decrease in intracellular Mg, caused by Mg deficiency, was reported to release the Mg-mediated inhibition of the renal outer medullary potassium (ROMK) channels and increase K secretion, whereas normally intracellular Mg is suggested to bind to ROMK and block K efflux/secretion.[@b18-dmso-11-389] Our study revealed that Mg supplementation significantly elevated the intracellular K levels ([Figure 3](#f3-dmso-11-389){ref-type="fig"}) might include these dual effects of the Mg stimulatory effect on the Na-K-ATPase and the blocking effect of Mg on the K-efflux due to the ROMK channel. Mg deficiency may further impair Na-K-ATPase activity, which would contribute to K wasting and decreased cellular uptake of K.[@b19-dmso-11-389] The observed difference between the obese and nonobese groups could potentially imply that the Na-K-ATPase activity might be impaired more in the obese group, leading to the higher intracellular K levels.

The ability of Mg supplementation to diminish the levels of CRP, TNF-α, and other biomarkers of inflammation and ROS/RNS stress has been previously reported.[@b20-dmso-11-389] However, Guerrero-Romero et al reported that only metabolic syndrome patients with severe hypomagnesemia (\<0.49 mmol/L) had elevated levels of CRP and TNF-α.[@b21-dmso-11-389] In our study patients, the severity of hypomagnesemia was mild (=0.49 and \<0.74 mmol/L), but we observed a significant decrease in TNF-α levels, while no significant effect was observed for CRP levels at the end of treatment.

Among our study patients, 85% were on statin therapy. It has been reported that statin therapy can affect plasma levels of inflammatory markers; statin therapy has been shown to specifically lower plasma levels of CRP levels.[@b22-dmso-11-389]--[@b25-dmso-11-389] It is also known that statins have antioxidant effects by inhibiting the activity of oxidant enzymes, such as those of nicotinamide adenine dinucleotide phosphate oxidase and myeloperoxidase, and by upregulating the activity of antioxidant enzymes, eg, catalase, and enhancing endothelial nitric oxide bioavailability.[@b26-dmso-11-389],[@b27-dmso-11-389]

Diabetes mellitus may also be associated with enhanced lipid peroxidation and persistent platelet activation. It has been shown that the in vivo formation of 8-isoprostane, which is a bioactive product of arachidonic acid peroxidation, was increased in patients with diabetes mellitus.[@b28-dmso-11-389] Thus, monitoring changes in either plasma or urinary 8-isoprostane levels can provide an important biochemical link between impaired glycemic control and persistent systemic oxidative stress.

Oxidative (free radical) stress has been implicated as a major underlying mechanism behind many acute and chronic diseases, including type 2 diabetes.[@b29-dmso-11-389] However, the measurement of the levels of free radicals or their end products is complicated. Isoprostanes, which are derived from the nonenzymatic peroxidation of arachidonic acid, are now considered to be reliable biomarkers of oxidant stress in the human body. Free 8-isoprostane has been the most commonly measured F2-isoprostane to date and has been used as the gold standard index of in vivo oxidative stress.[@b30-dmso-11-389] Our basic research laboratory routinely measures the free levels of plasma 8-isoprostane as a representative index of oxidative stress in rats experiencing hypomagnesemia or cancer drug toxicity.[@b31-dmso-11-389]--[@b33-dmso-11-389] In patients with type 2 diabetes, elevated levels of 8-isoprostane in urine and blood have been observed.[@b29-dmso-11-389] However, due to patient variability, in a typical clinical study, not all patients with type 2 diabetes display elevated blood isoprostane levels.[@b34-dmso-11-389] In our study, approximately half of the patients had normal plasma 8-isoprostane levels at ≤50 pg/mL; on average, the plasma free 8-isoprostane levels in healthy individuals were reviewed and estimated to be 45±18 pg/mL.[@b30-dmso-11-389] In our study, approximately one third of our patient cohort (n=15) displayed elevated isoprostane levels at ≥80 pg/mL at the beginning of study. Therefore, we chose this subset of patients to determine whether Mg supplementation would have an effect. As represented in [Figure 2](#f2-dmso-11-389){ref-type="fig"}, the average isoprostane level of these 15 patients at the baseline was 91.7±21.8 pg/mL. At the end of the study, the average 8-isoprostane level was significantly reduced to 71.7±27.5 pg/mL (*p*=0.0323), suggesting that for individuals with high indices of oxidative stress, attenuation of the stress was achieved after 3 months. In a separate analysis to compare the treatment effects on changes in isoprostane levels between the obese and nonobese groups (25 patients were selected), significant reduction in the isoprostane level was observed at 3 months in the obese group, although nonsignificant decreases were also found in the nonobese group.

Conclusion
==========

Our data showed that oral Mg-l-lactate replacement therapy after 3 months of treatment with an average dose of 336 mg daily corrected hypomagnesemia and had an anti-inflammatory effect in patients with type 2 diabetes. Oral Mg supplementation significantly increased the intracellular and serum levels. Statistically, clinical improvement in HbA1c and CRP levels was not observed at the end of the study, but a significant decrease in the inflammatory biomarker TNF-α as well as in the oxidative biomarker isoprostane was evident.

We were able to employ a feasible and precise method for assessing intracellular Mg level in noninvasively obtained tissue samples, to routinely determine intracellular Mg levels. The findings of this clinical trial are important for understanding the role of hypomagnesemia in diabetes patients and may provide support for this therapeutic approach for improving insulin sensitivity in patients with type 2 diabetes. We suggest that Mg serum levels and, potentially, cellular levels should always be routinely determined for patients with type 2 diabetes and that hypomagnesemia, if present, should be corrected with Mg supplementation. Especially in a country as Kuwait and the Gulf Cooperation Council in general where the major source of drinking water is desalinated water in which Mg may be less available than from regular groundwater presumably leading to a diet low in Mg.[@b35-dmso-11-389],[@b36-dmso-11-389]

A longer intervention period of at least 4 months and/or higher doses of Mg, or dosage adjustment according to body weight, might be necessary to provide significant changes in HbA1c levels. We hypothesize that a larger clinical trial that includes nonobese and obese participants with type 2 diabetes taking into consideration the average Mg content in the diet would be feasible. We further recommend studying the extent to which replenishing Mg stores, particularly intracellular Mg leads to decreased insulin resistance.

Data availability
=================

Data related to this clinical trial, de-identified, can be shared with interested researchers immediately after publication including a detailed clinical trial report and the study protocol. All of the individual participant data collected during the trial are stored electronically and can be made available with no end date through contacting the principal investigators of this trial (<https://clinicaltrials.gov/ct2/show/NCT01980459>).

Supplementary materials
=======================

At study initiation, 62 patients were allocated to receive magnesium L-lactate tablets. Eight participants were excluded prior to receiving the intervention, and seven participants dropped out of the study. Reasons for exclusion were as follows: abnormal ECGs (four participants), two participants were no longer interested in participating, one participant left the country, and one participant concurrently started another magnesium supplement (magnesium oxide tablets). Seven participants dropped out of the study and discontinued taking the intervention. Reasons for dropping out were as follows: three participants could not commit to sample collection appointments, two participants travelled abroad during the study period, and two participants were doubtful of the benefit of the tablets.

###### 

The study flow diagram, detailing the phases of the trial including enrollment, intervention allocation, follow-up, and data analysis.

###### 

Demographics and clinical characteristics of the study population at baseline and at the end of 3-month therapy

                                    Patients (n=47)   Obese group (n= 32)   Nonobese group (n=15)                                                                       
  --------------------------------- ----------------- --------------------- ----------------------- ------------------------------------------------------- ----------- ------------
  Age                               52±10.2           --                    50.5±10.6               --                                                      55.2±8.9    --
  Gender                                                                                                                                                                
   Men                              25                25                    14                      14                                                      11          11
   Women                            22                22                    18                      18                                                      4           4
  BMI (kg/m^2^)                     32.32±5.6         32.8±5.9              35.2±4.4                35.7±4.9                                                26.2±1.8    26.7±1.8
  Weight (kg)                       89.9±17.3         91.4±18.5\*\*         96.3±17.1               97.7±18.6[\*](#tfn8-dmso-11-389){ref-type="table-fn"}   76.4±7.5    77.9±8.1
  Systolic blood pressure (mmHg)    128.5±12.8        135±14.5\*\*\*        130.1±13.2              136.9±14.5\*\*                                          125±11.4    130.8±13.9
  Diastolic blood pressure (mmHg)   70.5±12           72±15.9               70.6±12.8               71.4±17.5                                               70.3±10.5   73.3±12.1
  Heart rate                        83.9±10.5         83.5±12.8             83.4±11.3               84.8±11.4                                               85±8.7      80.6±15.4
  Creatinine (μmol/L)               73.5±14.6         76.6±20.2             72±13.2                 76.1±20.9                                               76.7±17.4   77.5±19
  eGFR (mL/min/1.73m^2^)            88.6±17.1         85.5±19.9             89.3±17.1               84.9±20.2[\*](#tfn8-dmso-11-389){ref-type="table-fn"}   87.2±17.8   86.7±19.8

**Notes:** Values are mean ± SD.

*p*-value between baseline and end. Creatinine (Cr) normal level: 71--115 (μmol/L).

**Abbreviations:** BMI, body mass index; eGFR, estimated glomerular filtration rate.

This study was funded by a grant through the Kuwait Foundation for the Advancement of Science "Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis (2013-1302-01) and the DDI (RA 2012-013). The study was registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) (<https://clinicaltrials.gov/ct2/show/NCT01980459>).
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![Serum magnesium levels (mmol/L) in (**A**) all patients after 12-week supplementation and (**B**) all patients grouped into nonobese or obese comparing two groups of all patients; intracellular magnesium levels (mEq/L) in (**C**) all patients after 12-week supplementation and (**D**) all patients grouped into nonobese or obese comparing two groups of all patients. \*\**p*=0.0019, \*\*\**p*=0.0003, ^\*\*\*\*^*p*\<000.1, ^\#^*p*=0.0077, ^\#\#^*p*=0.0002.](dmso-11-389Fig1){#f1-dmso-11-389}

![Serum levels of TNF-α (**A**), CRP (**B**), and isoprostane (**C**) after 3-month oral Mg supplementation in all patients and grouped into obese (black) and nonobese (gray) subjects (**B**, **D**, **F**). TNF-α; ^\*\*\*\*^*p*\<0.0001, \*\**p*=0.0060. CRP was observed to be nonsignificant (ns). The red line indicates TNF-α level ≥3.5 pg/mL defined as low-grade inflammation. Isoprostane: ^\*^*p*=0.0323; \*\*\**p*=0.0394.\
**Abbreviations:** CRP, C-reactive protein; TNF-α, tumor necrosis factor-α.](dmso-11-389Fig2){#f2-dmso-11-389}

![Intracellular potassium levels (mEq/L) in all patients (**A**) after 12-week supplementation and all patients subgrouped into nonobese (gray) or obese (black) ^\*^*p*=0.0030 (**B**) comparing the two patient groups, \*\**p*=00025.\
**Abbreviation:** ns, nonsignificant.](dmso-11-389Fig3){#f3-dmso-11-389}

###### 

Laboratory evaluation before and after treatment of the study population at baseline and at the end of 3-month therapy

  Outcome                            Patients (n=47)                                         Obese group (n=32)                                            Nonobese group (n=15)                                                                                      
  ---------------------------------- ------------------------------------------------------- ------------------------------------------------------------- ----------------------- ------------------------------------------------------------ --------------------- ----------------------------------------------------------
  HbA1c (%) (mmol/mmol)              8.1±1.7 (64.6±18.8)                                     7.9±1.6 (63.4±17.0)                                           8.4±1.8 (67.8±19.6)     8.1±1.6 (64.8±17.9)                                          7.5±1.5 (57.7±15.5)   7.6±1.4 (60.2±15.1)
  Magnesium (serum; mmol/L)          0.71±0.06                                               0.73±0.06[\*\*\*\*](#tfn5-dmso-11-389){ref-type="table-fn"}   0.70±0.06               0.73±0.06[\*\*\*](#tfn4-dmso-11-389){ref-type="table-fn"}    0.71±0.05             0.74±0.05[\*\*](#tfn3-dmso-11-389){ref-type="table-fn"}
  Magnesium (intracellular; mEq/L)   33.1±1.25                                               35.5±5.6[\*\*](#tfn3-dmso-11-389){ref-type="table-fn"}        32.9±1.2                34.9±6.5[\*\*\*\*](#tfn5-dmso-11-389){ref-type="table-fn"}   33.5±1.2              36.8±2.1[\*\*\*](#tfn4-dmso-11-389){ref-type="table-fn"}
  Potassium (intracellular; mEq/L)   144.3±47.6                                              184.7±73.4[\*\*](#tfn3-dmso-11-389){ref-type="table-fn"}      144.7±48.7              199.2±80.8[\*\*](#tfn3-dmso-11-389){ref-type="table-fn"}     143.4±46.8            154.7±43.1
  CRP (mg/dL)                        0.59±0.65                                               0.54±0.52                                                     0.58±0.58               0.7±0.86                                                     0.61±0.8              0.43±0.4
  TNF-α (pg/mL)                      9.1±1.7                                                 6.1±2.7[\*\*\*\*](#tfn5-dmso-11-389){ref-type="table-fn"}     9.1±1.9                 5.7±2.5[\*\*\*\*](#tfn5-dmso-11-389){ref-type="table-fn"}    9.1±1.25              6.8±3.1[\*\*](#tfn3-dmso-11-389){ref-type="table-fn"}
  Isoprostane (pg/mL)                91.7±21.8[\#](#tfn1-dmso-11-389){ref-type="table-fn"}   71.7±27.5[\*](#tfn2-dmso-11-389){ref-type="table-fn"}         71.75±29.6              58±27.8[\*](#tfn2-dmso-11-389){ref-type="table-fn"}          78.5±29.4             60.1±30.5

**Notes:** Data are mean ± SD. Values are mean ± SD.

n=15 for patients with isoprostane levels =80 pg/mL at baseline. Serum magnesium normal reference range: 0.74--0.99 mmol/L. Intracellular magnesium reference range: 34.0--42.0 mEq/L. Potassium reference range: 80.0--240.0 mEq/L. HbA1c reference range: 4%--6% NGSP, 20--42 mmol/mol IFCC).

*p*≤0.05, *p*-value between baseline and end;

*p*≤0.01;

*p*≤0.001;

*p*≤0.0001.

**Abbreviations:** CRP, C-reactive protein; IFCC, International Federation of Clinical Chemistry; HbA1c, hemoglobin A1c; TNF-α, tumor necrosis factor-α.
